Partially concordant with our in vivo findings, the research of Xiong et al. ascertained that OLR1 upregulation caused by GSTM3TV2 was capable of augmenting chemoresistance in nude mice with subcutaneously injected pancreatic cancer cells and treated with gemcitabine [9]. The gene discussed is OLR1; the disease is pancreatic neoplasm.